Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: Target engagement, tolerabilityand pharmacokinetics in humans

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 83, Issue 9, 2012, Pages 894-902

  Maccecchini, Maria L ^a   Chang, Mee Young ^a   Pan, Catherine ^b   John, Varghese ^c   Zetterberg, Henrik ^d   Greig, Nigel H ^e  

^a QR Pharma Inc   (United States)

^b Inarian Neurodiagnostics LLC   (United States)

^c BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID ALPHA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; AMYLOID TAU PROTEIN; BIOLOGICAL MARKER; CD14 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT FACTOR H; DRUG METABOLITE; MONOCYTE CHEMOTACTIC PROTEIN 1; N1 NORPOSIPHEN; N1, N8 BISNORPOSIPHEN; N8 NORPOSIPHEN; PHENSERINE; PLACEBO; PROTEIN YKL 40; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BODY TEMPERATURE DISORDER; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEART RATE; HUMAN; HUMAN VERSUS ANIMAL COMPARISON; LIPOPHILICITY; MALE; MAXIMUM PLASMA CONCENTRATION; MILD COGNITIVE IMPAIRMENT; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PAIN; PHASE 1 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; RAT; SIDE EFFECT; SINGLE DRUG DOSE; STEADY STATE; SYNCOPE; TIME TO MAXIMUM PLASMA CONCENTRATION; TREND STUDY; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 84864803418     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2012-302589     Document Type: Article

References (43)

1. Stone JG, Casadesus G, Gustaw-Rothenberg K, et al. Frontiers in Alzheimer's disease therapeutics. Ther Adv Chronic Dis 2011;2:9-23.
2. Sambamurti K, Greig NH, Lahiri DK. Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer's disease. Neuromolecular Med 2002;1:1-31. (Pubitemid 37021521)
3. Sambamurti K, Suram A, Venugopal C, et al. A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. Curr Alzheimer Res 2006;3:81-90.
4. Selkoe DJ. Alzheimer's disease. Cold Spring Harb Perspect Biol 2011;3:pii: a004457.
5. Popp J, Arlt S. Pharmacological treatment of dementia and mild cognitive impairment due to Alzheimer's disease. Curr Opin Psychiatry 2011;24:556-61.
6. Selkoe DJ. Defining molecular targets to prevent Alzheimer disease. Arch Neurol 2005;62:192-5. (Pubitemid 40204739)
7. Ashe KH, Zahs KR. Probing the biology of Alzheimer's disease in mice. Neuron 2010;66:631-45.
8. De Felice FG, Velasco PT, Lambert MP, et al. Aβ oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. J Biol Chem 2007;282:11590-601. (Pubitemid 47100810)
9. Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008;14:837-42.
10. Nikolaev A, McLaughlin T, O'Leary DD, et al. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009;457:981-9.
11. Galvan V, Gorostiza OF, Banwait S, et al. Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664. Proc Natl Acad Sci U S A 2006;102:7130-5.
12. Harris JA, Devidze N, Halabisky B, et al. Many neuronal and behavioral impairments in transgenic mouse models of Alzheimer's disease are independent of caspase cleavage of the amyloid precursor protein. J Neurosci 2010; 30:372-81.
13. Lahiri DK, Chen D, Maloney B, et al. The experimental Alzheimer's disease drug Posiphen lowers A b peptide levels in cell culture and mice. J Pharmacol Exp Ther 2007;320:386-96. (Pubitemid 46025753)
14. Shaw K, Utsuki T, Rogers JT, et al. Phenserine regulates translation of β-amyloid precursor protein mRNA by a putative interleukin-1 responsive element: a novel target for drug development. Proc Natl Acad Sci U S A 2001;98:7605-10. (Pubitemid 32567995)
15. Rogers JT, Randall JD, Cahill CM, et al. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 2002; 277:45518-28. (Pubitemid 36159162)
16. Cho HH, Cahill CM, Vanderburg CR, et al. Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1. J Biol Chem 2010; 285:31217-32.
17. Greig NH, Sambamurti K, Yu QS, et al. An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. Curr Alzheimer Res 2005;2:281-90. (Pubitemid 40980186)
18. Marutle A, Ohmitsu M, Nilbratt M, et al. Modulation of human neural stem cell differentiation in Alzheimer (APP23) transgenic mice by phenserine. Proc Natl Acad Sci U S A 2007; 104 :12506-11. (Pubitemid 47206168)
19. Yu QS, Greig NH, Holloway HW, et al. Syntheses and anticholinesterase activities of (3aS)-N(1), N(8)-bisnorphenserine(3aS)-N(1), N(8)- bisnorphysostigmine, their antipodal isomers, and other potential metabolites of phenserine. J Med Chem 1998;41:2371-9. (Pubitemid 28285739)
20. Yu QS, Pei XF, Holloway HW, et al. Total syntheses and anticholinesterase activities of (3aS)-N(8)-norphysostigmine, (3aS)-N(8)-norphenserine, their antipodal isomers, and other N(8)-substituted analogues. J Med Chem 1997;40:2895-901. (Pubitemid 27382540)
21. Soares H, Raha N, Sikpi M, et al. Aβ variability and effects of γ-secretase inhibition on plasma and CSF levels of Aβ in healthy volunteers. Poster P1-264. International Conference on Alzheimer's Disease, Vienna, Austria: Alzheimer's Association, 2009.
22. Ereshefsky L, Jhee S, Yen M, et al. Cerebrospinal fluid beta-amyloid and dynabridging in Alzheimer's disease drug development. Biomark Med 2009;3:711-21.
23. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004;256:183-94. (Pubitemid 39222988)
24. Mattsson N, Tabatabaei S, Johansson P, et al. Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility. Neuromolecular Med 2011;13:151-9.
25. Hong Z, Shi M, Chung KA, et al. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 2010; 133:713-26.
26. Yin GN, Jeon H, Lee S, et al. Role of soluble CD14 in cerebrospinal fluid as a regulator of glial functions. J Neurosci Res 2009;87:2578-90.
27. Salehi M, Faizi R, Takimoto J, et al . Examining the effects of (+)-phenserine in Ts65Dn mouse model of Down syndrome. Alzheimers Dement 2008;4 :T462-3.
28. Rogers JT, Mikkilineni S, Cantuti-Castelvetri I, et al. The alpha-synuclein 5'- untranslated region targeted translation blockers: anti-alpha synuclein efficacy of cardiac glycosides and Posiphen. J Neural Transm. 2011;118:493-507.
29. Bacchetti P, Deeks SG, McCune JM. Breaking free of sample size dogma to perform innovative translational research. Sci Transl Med 2011;3:87ps24.
30. Bateman RJ, Wen G, Morris JC, et al. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker. Neurology 2007;68:666-9. (Pubitemid 46667813)
31. Huang Y, Potter R, Sigurdson W, et al. Effects of age and amyloid deposition on aβ dynamics in the human central nervous system. Arch Neurol 2012; 69:51-8.
32. Lewczuk P, Kamrowski-Kruck H, Peters O, et al. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry 2010; 15:138-45.
33. Perneczky R, Tsolakidou A, Arnold A, et al. CSF soluble amyloid precursor proteins in the diagnosis of incipient Alzheimer disease. Neurology 2011;77:35-8.
34. Alexopoulos P, Tsolakidou A, Roselli F, et al. Clinical and neurobiological correlates of soluble amyloid precursor proteins in the cerebrospinal fluid. Alzheimers Dement. Published Online First: 4 November 2011.
35. Shaw LM, Korecka M, Clark CM, et al. Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov 2007;6 :295-303. (Pubitemid 46505880)
36. Seppälä TT, Koivisto AM, Hartikainen P, et al. Longitudinal changes of CSF biomarkers in Alzheimer's disease. J Alzheimers Dis 2011;25:583-94.
37. Buchhave P, Minthon L, Zetterberg H, et al. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 2012;69:98-106.
38. Shaw LM, Vanderstichele H, Knapik-Czajka M, et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009;65:403-13.
39. Bottley A, Phillips NM, Webb TE, et al. eIF4A inhibition allows translational regulation of mRNAs encoding proteins involved in Alzheimer's disease. PLoS One 2010;5 :pii: e13030.
40. Veo BL, Krushel LA. Translation initiation of the human tau mRNA through an internal ribosomal entry site. J Alzheimers Dis 2009;16:271-5.
41. Reichwald J, Danner S, Wiederhold KH, et al. Expression of complement system components during aging and amyloid deposition in APP transgenic mice. J Neuroinflammation 2009;6:35.
42. Wang Y, Hancock AM, Bradner J, et al. Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am J Pathol 2011; 178 :1509-16.
43. Mikkilineni S, Cantuti-Castelvetri I, Cahill C, et al. The anti-cholinesterase phenserine and its enantiomer Posiphen as 5′ untranslated region directed translation blockers of the Parkinson's alpha synuclein expression. Parkinson's Dis 2012;2012: 142372.